European Archives - Page 796 of 1216 - European Medical Journal

Epithelial Barrier Dysfunction in Type 2 Inflammatory Diseases

Type 2 immunity evolved from a dialogue between the immune system and microbes. This form of immunity confers protection against bacteria, viruses…

Dermatomyositis Revealing Bladder Cancer Recurrence

There is a well-recognised association between inflammatory dermatomyopathy, dermatomyositis, and underlying visceral malignancy in adults.

Near Circumferential Invasive Proliferative Gelatinous Mass in the Calf: An Unusual Presentation of Hidradenitis Suppurativa

Hidradenitis suppurativa, or acne inversa, is a chronic, recurrent inflammatory disease of the skin and subcutaneous tissue characterised by painful…

Serum Sickness-Like Reaction in Children: Review of the Literature

The main objective of this manuscript is to offer an organised and updated review of the clinical features and current treatment options for paediatric serum sickness-like reaction.

Rosacea: The Patient Experience is Now 'CLEAR'

Prof Schaller posed the question “what makes rosacea so special?” and explained that the manifestations of rosacea are very varied, including papules…

Autoimmune Bullous Skin Disorder Induced by PD-1 Inhibitors

Immune checkpoint inhibitors are important therapeutic modalities not only against metastatic melanoma, but in other malignant disorders, including…

Analysis of Methods of the Demodex Mites Diagnosis

Demodex mites are microscopic arthropods that present in the pilosebaceous units of the human skin.1,2 Demodex mites support the severity of the inflammatory process in dermatoses such as acne, rosacea, seborrheic…

IL-23 Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Review of Clinical Efficacy, Safety, and Tolerability

Psoriasis is a common, chronic, immune-mediated skin disease affecting approximately 2–3% of the global population…

Apulian Experience with the Innovative Drug for Atopic Dermatitis: Dupilumab

Four patients with long-standing atopic dermatitis (AD) with elevated Eczema Area and Severity Index (EASI) and nonresponders to common therapies…

Cutaneous Adverse Effects Induced by Nivolumab

Nivolumab is a humanised IgG4 monoclonal antibody that binds the programmed cell death protein 1 (PD-1) receptor and blocks interaction with its ligand…